| |
Patients (%)
|
mOS months (95% CI)
|
P-value
|
|---|
|
Age
|
|
<60
|
203 (50.5)
|
11.6 (10.1-13.2)
|
0.808
|
|
≥ 60
|
199 (49.5)
|
12.0 (9.9-14.1)
| |
|
Gender
|
|
Male
|
293 (72.9)
|
11.7 (10.1-13.3)
|
0.952
|
|
Female
|
109 (27.1)
|
12.1 (10.6-13.6)
| |
|
Liver Mets
|
|
Yes
|
125 (31.1)
|
11.4 (8.5-14.3)
|
0.352
|
|
No
|
277 (68.9)
|
12.0 (10.7-13.3)
| |
|
Peritoneal Mets
|
|
Yes
|
159 (39.6)
|
9.9 (8.4-11.5)
|
0.023
|
|
No
|
243 (60.4)
|
13.0 (11.2-14.8)
| |
|
Bone Mets
|
|
Yes
|
28 (7.0)
|
8.2 (7.1-9.3)
|
0.117
|
|
No
|
374 (93.0)
|
12.1 (10.9-13.2)
| |
|
Albumin
|
|
<3.5
|
77 (19.2)
|
7.7 (5.9-9.5)
|
0.001
|
|
≥ 3.5
|
325 (80.8)
|
12.4 (10.7-14.2)
| |
|
CRP
|
|
≤ 1
|
262 (64.9)
|
14.8 (12.7-17.0)
|
0.001
|
|
>1
|
140 (34.8)
|
8.7 (7.3-10.2)
| |
|
ECOG PS
|
|
0-1
|
329 (81.8)
|
12.4 (10.9-13.8)
|
0.003
|
|
≥ 2
|
73 (48.2)
|
8.7 (7.3-10.0)
| |
|
GPS
|
|
0
|
238 (59.2)
|
15.3 (13.1-17.5)
|
0.001
|
|
1
|
111 (27.6)
|
8.9 (7.2-10.7)
| |
|
2
|
53 (13.2)
|
7.6 (4.9-10.2)
| |
- mOS: median overall survival, Mets: metastasis, CRP: C-reactive protein, ECOG PS: Eastern Cooperative Oncology Group, performance status, GPS: Glascow prognostic score
